心力衰竭护理的经济学
Chen Wei1, Paul A Heidenreich2, Alexander T Sandhu2
1Department of Medicine, Stanford University School of Medicine, United States of America.
Progress in cardiovascular diseases
|January 20, 2024
概括
心力衰竭治疗提供了不同的经济价值. 准则导向的医学疗法具有成本效益,但改善患者获得负担得起的治疗方法对于减少心力衰竭的经济负担至关重要.
科学领域:
- 卫生经济学 卫生经济学
- 心血管医学 心血管医学
- 药物经济学 药物经济学
背景情况:
- 心力衰竭 (HF) 在美国是一个巨大的经济负担,预计到2030年将花费7000亿美元.
- 成本效益分析对于评估高频处理的经济价值至关重要.
- 改善患者获得HF治疗的机会对于管理医疗保健成本至关重要.
研究的目的:
- 审查各种心力衰竭治疗的成本效益.
- 确定提高患者获得HF治疗的策略.
- 讨论高频管理对经济的影响.
主要方法:
- 对HF治疗的成本效益研究的系统审查.
- 对减少喷射分数的HF指南导向医学疗法 (GDMT) 的分析.
- 对手术和先进的HF疗法进行经济价值评估.
主要成果:
- 降低射出分数的HF的GDMT通常具有高的经济价值,而-葡萄糖共运输体-2抑制剂显示中等价值.
- 医疗治疗的四个支柱的联合治疗具有中等的经济价值 (73,000美元98,500美元/经质量调整的生命年).
- 高经济价值的程序包括心脏再同步装置,植入式心脏转换器-除器和冠状动脉旁路手术;先进的HF疗法显示改善了经济价值.
结论:
- 需要努力解决负担能力的挑战,并确保最佳的HF护理.
- 像"通货膨胀减缓法"这样的政策改革可能会改善药品价格和患者获取.
- 提高患者和医生对医疗成本的认识,以及更广泛的获取举措,对于减少HF的临床和经济影响至关重要.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591